FIGURE 67. Proportion of cohort alive over time with model fit by MMSE (a), Barthel ADL Index (b) and age all at the start of the study (c).

FIGURE 67Proportion of cohort alive over time with model fit by MMSE (a), Barthel ADL Index (b) and age all at the start of the study (c)

(a) lower curve MMSE = 10, middle curve MMSE = 14.5 (mean), upper curve MMSE = 20; (b) lower curve Barthel = 10, middle curve Barthel = 17 (mean), upper curve Barthel = 20; (c) lower curve age = 85 years, middle curve age = 78 years (mean), upper curve age = 70 years.

From: 6, The Peninsula Technology Assessment Group cost–utility assessment

Cover of The Effectiveness and Cost-Effectiveness of Donepezil, Galantamine, Rivastigmine and Memantine for the Treatment of Alzheimer's Disease (Review of Technology Appraisal No. 111): A Systematic Review and Economic Model
The Effectiveness and Cost-Effectiveness of Donepezil, Galantamine, Rivastigmine and Memantine for the Treatment of Alzheimer's Disease (Review of Technology Appraisal No. 111): A Systematic Review and Economic Model.
Health Technology Assessment, No. 16.21.
Bond M, Rogers G, Peters J, et al.
Southampton (UK): NIHR Journals Library; 2012 Apr.
© 2012, Crown Copyright.

Included under terms of UK Non-commercial Government License.

PubMed Health. A service of the National Library of Medicine, National Institutes of Health.